Covered recipient · General Payments record
ROBYN DAWN HARTVICKSON
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$862.16
54 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $862.16 | 54 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $217.14 | 11 |
| PFIZER INC. | $207.21 | 16 |
| Astellas Pharma US Inc | $95.05 | 6 |
| Novo Nordisk Inc | $74.83 | 4 |
| Amgen Inc. | $50.21 | 3 |
| Lilly USA, LLC | $48.56 | 3 |
| Bayer Healthcare Pharmaceuticals Inc. | $32.73 | 2 |
| Sumitomo Pharma America, Inc. | $31.70 | 2 |
| Merck Sharp & Dohme LLC | $30.60 | 2 |
| AstraZeneca Pharmaceuticals LP | $26.58 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.81 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.46 | 1 |
| Novartis Pharmaceuticals Corporation | $14.28 | 1 |
Page 1 of 2; records 1–50 of 54 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROBYN DAWN HARTVICKSON
NPI 1679532659 · CMS profile ID 303021
Allopathic & Osteopathic Physicians / Family Medicine
NEWTON, KS
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 2; records 1–50 of 54 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1679532659?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 54 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679532659?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 54 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679532659?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 54 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1679532659?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
54 matching records · $862.16 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–50 of 54.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $20.43 | 12/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115707625 | CMS |
| PFIZER INC. | $21.24 | 11/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131079805 | CMS |
| PFIZER INC. | $9.09 | 11/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132072744 | CMS |
| PFIZER INC. | $0.91 | 11/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132105028 | CMS |
| Sumitomo Pharma America, Inc. | $17.03 | 11/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148862349 | CMS |
| PFIZER INC. | $10.36 | 11/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130890581 | CMS |
| Amgen Inc. | $14.80 | 11/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115707619 | CMS |
| Astellas Pharma US Inc | $15.47 | 11/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139420883 | CMS |
| ABBVIE INC. | $18.47 | 10/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103887375 | CMS |
| PFIZER INC. | $5.55 | 10/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132102363 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.21 | 10/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104594254 | CMS |
| PFIZER INC. | $17.13 | 10/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131943676 | CMS |
| Merck Sharp & Dohme LLC | $14.48 | 10/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141788946 | CMS |
| ABBVIE INC. | $14.58 | 10/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103887373 | CMS |
| PFIZER INC. | $17.72 | 09/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131955312 | CMS |
| ABBVIE INC. | $17.38 | 09/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103887371 | CMS |
| Novo Nordisk Inc | $17.43 | 09/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1097650775 | CMS |
| PFIZER INC. | $10.35 | 09/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131871453 | CMS |
| Astellas Pharma US Inc | $13.42 | 09/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139383658 | CMS |
| ABBVIE INC. | $16.63 | 08/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103887369 | CMS |
| PFIZER INC. | $15.47 | 08/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131842190 | CMS |
| Novartis Pharmaceuticals Corporation | $14.28 | 08/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086934801 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.46 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153704996 | CMS |
| PFIZER INC. | $17.82 | 08/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131856750 | CMS |
| PFIZER INC. | $17.13 | 08/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131844939 | CMS |
| Astellas Pharma US Inc | $16.28 | 08/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139280592 | CMS |
| Novo Nordisk Inc | $18.28 | 08/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1097072380 | CMS |
| Sumitomo Pharma America, Inc. | $14.67 | 07/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148862347 | CMS |
| Astellas Pharma US Inc | $13.42 | 07/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139283694 | CMS |
| PFIZER INC. | $13.52 | 07/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131744154 | CMS |
| Lilly USA, LLC | $15.76 | 07/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135374854 | CMS |
| Amgen Inc. | $14.98 | 07/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117574366 | CMS |
| PFIZER INC. | $1.47 | 07/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131786994 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.81 | 07/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118106425 | CMS |
| Merck Sharp & Dohme LLC | $16.12 | 07/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141969613 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $16.14 | 06/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086197028 | CMS |
| Novo Nordisk Inc | $14.36 | 06/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1096992827 | CMS |
| ABBVIE INC. | $16.82 | 06/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103887367 | CMS |
| PFIZER INC. | $18.05 | 06/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131616977 | CMS |
| ABBVIE INC. | $26.39 | 06/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103887365 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.37 | 06/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105203774 | CMS |
| PFIZER INC. | $17.13 | 06/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131435014 | CMS |
| ABBVIE INC. | $20.12 | 05/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103887363 | CMS |
| ABBVIE INC. | $23.80 | 05/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103887361 | CMS |
| Astellas Pharma US Inc | $18.96 | 05/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139336164 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $16.59 | 04/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086139253 | CMS |
| ABBVIE INC. | $16.97 | 03/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103887359 | CMS |
| ABBVIE INC. | $22.88 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103887357 | CMS |
| Lilly USA, LLC | $16.43 | 02/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135386799 | CMS |
| Astellas Pharma US Inc | $17.50 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139313926 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $136,207.90 | 39 |
| PY2024 | Principal investigator | $344,898.92 | 54 |
| PY2023 | Principal investigator | $702,129.77 | 95 |
| PY2022 | Principal investigator | $153,146.27 | 62 |
| PY2021 | Principal investigator | $143,310.07 | 45 |
| PY2020 | Principal investigator | $223,270.91 | 168 |
| PY2019 | Principal investigator | $302,825.41 | 141 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
95 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Novavax Inc | $25,040.10 | 12/21/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines | No dispute reported | 06/30/2026 | 1055259643 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $738.00 | 12/20/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT | No dispute reported | 06/30/2026 | 1127786141 |
| Principal investigator 1 | ModernaTX, Inc. | $3,600.00 | 12/20/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041719987 |
| Principal investigator 1 | ModernaTX, Inc. | $15,523.30 | 12/20/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041720945 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $860.40 | 12/06/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT | No dispute reported | 06/30/2026 | 1127786139 |
| Principal investigator 1 | Novavax Inc | $1,104.00 | 11/29/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines | No dispute reported | 06/30/2026 | 1055263541 |
| Principal investigator 1 | ModernaTX, Inc. | $12,624.95 | 11/22/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041720831 |
| Principal investigator 1 | Novavax Inc | $1,846.44 | 11/22/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines | No dispute reported | 06/30/2026 | 1055262631 |
| Principal investigator 1 | Novavax Inc | $10,155.22 | 11/22/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines | No dispute reported | 06/30/2026 | 1055265551 |
| Principal investigator 1 | Novavax Inc | $1,050.54 | 11/09/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines | No dispute reported | 06/30/2026 | 1055259641 |
| Principal investigator 1 | Novavax Inc | $125,281.92 | 11/02/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines | No dispute reported | 06/30/2026 | 1055266539 |
| Principal investigator 1 | ModernaTX, Inc. | $64,909.00 | 11/01/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041720835 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $146.70 | 10/27/2023 | Non-covered Recipient Entity NEW ORLEANS CENTER FOR CLINICAL RESEARCH | A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT | No dispute reported | 06/30/2026 | 1127785797 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $110.00 | 10/27/2023 | Non-covered Recipient Entity NEW ORLEANS CENTER FOR CLINICAL RESEARCH | A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT | No dispute reported | 06/30/2026 | 1127786135 |
| Principal investigator 1 | ModernaTX, Inc. | $18,639.40 | 10/25/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041720817 |
| Principal investigator 1 | Organon LLC | $920.00 | 10/25/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016113557 |
| Principal investigator 1 | Organon LLC | $920.00 | 10/25/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016113571 |
| Principal investigator 1 | PFIZER INC. | $3,800.00 | 10/25/2023 | Non-covered Recipient Entity Alliance for MultiSpeciality Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045873678 |
| Principal investigator 1 | Novavax Inc | $11,000.00 | 10/19/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines | No dispute reported | 06/30/2026 | 1055263539 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,900.00 | 10/11/2023 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | Safety, Immunogenicity, Infectivity, and Dose-Finding Study of an Investigational Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers | No dispute reported | 06/30/2026 | 1035908449 |
| Principal investigator 1 | ModernaTX, Inc. | $841.00 | 10/05/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes | No dispute reported | 06/30/2026 | 1041697665 |
| Principal investigator 1 | ModernaTX, Inc. | $17,861.35 | 10/02/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041720805 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $796.50 | 09/27/2023 | Non-covered Recipient Entity NEW ORLEANS CENTER FOR CLINICAL RESEARCH | PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT | No dispute reported | 06/30/2026 | 1127785799 |
| Principal investigator 1 | PFIZER INC. | $717.72 | 09/23/2023 | Non-covered Recipient Entity Alliance for MultiSpeciality Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045911909 |
| Principal investigator 1 | Novavax Inc | $9,235.00 | 09/21/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055262289 |
| Principal investigator 1 | ModernaTX, Inc. | $143.70 | 09/20/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes | No dispute reported | 06/30/2026 | 1041697641 |
| Principal investigator 1 | Organon LLC | $1,602.00 | 09/20/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016110401 |
| Principal investigator 1 | ModernaTX, Inc. | $63.75 | 09/19/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes | No dispute reported | 06/30/2026 | 1041697653 |
| Principal investigator 1 | Novavax Inc | $400.00 | 09/14/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055259325 |
| Principal investigator 1 | PFIZER INC. | $754.07 | 09/02/2023 | Non-covered Recipient Entity Alliance for MultiSpeciality Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045865839 |
| Principal investigator 1 | ModernaTX, Inc. | $58,480.50 | 09/01/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041720741 |
| Principal investigator 1 | Organon LLC | $4,478.40 | 08/23/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016118925 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $954.00 | 08/18/2023 | Non-covered Recipient Entity NEW ORLEANS CENTER FOR CLINICAL RESEARCH | PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT | No dispute reported | 06/30/2026 | 1127786137 |
| Principal investigator 1 | ModernaTX, Inc. | $337.50 | 08/16/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, | No dispute reported | 06/30/2026 | 1041720681 |
| Principal investigator 1 | ModernaTX, Inc. | $182.00 | 08/04/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041720669 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 07/28/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041719907 |
| Principal investigator 1 | ModernaTX, Inc. | $762.25 | 07/26/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, | No dispute reported | 06/30/2026 | 1041720597 |
| Principal investigator 1 | Organon LLC | $3,822.30 | 07/21/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016092125 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,827.90 | 07/19/2023 | Non-covered Recipient Entity NEW ORLEANS CENTER FOR CLINICAL RESEARCH | A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO | No dispute reported | 06/30/2026 | 1127785787 |
| Principal investigator 1 | ModernaTX, Inc. | $112.50 | 07/19/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041720591 |
| Principal investigator 1 | ModernaTX, Inc. | $19,908.85 | 07/07/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041720585 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,798.10 | 06/21/2023 | Non-covered Recipient Entity NEW ORLEANS CENTER FOR CLINICAL RESEARCH | PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT | No dispute reported | 06/30/2026 | 1127785793 |
| Principal investigator 1 | Organon LLC | $784.80 | 06/21/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016086913 |
| Principal investigator 1 | Novavax Inc | $2,154.00 | 06/08/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055263255 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $110.00 | 06/02/2023 | Non-covered Recipient Entity NEW ORLEANS CENTER FOR CLINICAL RESEARCH | PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT | No dispute reported | 06/30/2026 | 1127785789 |
| Principal investigator 1 | ModernaTX, Inc. | $23,574.85 | 06/02/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041720573 |
| Principal investigator 1 | ModernaTX, Inc. | $8,035.00 | 06/01/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041721179 |
| Principal investigator 1 | PFIZER INC. | $150.00 | 05/25/2023 | Non-covered Recipient Entity Alliance for MultiSpeciality Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045910691 |
| Principal investigator 1 | Novavax Inc | $3,414.00 | 05/24/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055259323 |
| Principal investigator 1 | Organon LLC | $1,650.60 | 05/24/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016118611 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,346.40 | 05/19/2023 | Non-covered Recipient Entity NEW ORLEANS CENTER FOR CLINICAL RESEARCH | PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT | No dispute reported | 06/30/2026 | 1127785791 |
| Principal investigator 1 | Novavax Inc | $3,756.00 | 05/16/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055265231 |
| Principal investigator 1 | Novavax Inc | $1,508.00 | 05/09/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055264189 |
| Principal investigator 1 | ModernaTX, Inc. | $32,859.45 | 05/01/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041720391 |
| Principal investigator 1 | Novavax Inc | $1,850.00 | 04/26/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055260257 |
| Principal investigator 1 | Organon LLC | $784.80 | 04/19/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016118009 |
| Principal investigator 1 | Novavax Inc | $5,236.00 | 04/18/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055260261 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,121.30 | 04/14/2023 | Non-covered Recipient Entity NEW ORLEANS CENTER FOR CLINICAL RESEARCH | PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT | No dispute reported | 06/30/2026 | 1127785785 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,268.00 | 04/14/2023 | Non-covered Recipient Entity NEW ORLEANS CENTER FOR CLINICAL RESEARCH | PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT | No dispute reported | 06/30/2026 | 1127785795 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $146.70 | 04/14/2023 | Non-covered Recipient Entity NEW ORLEANS CENTER FOR CLINICAL RESEARCH | PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT | No dispute reported | 06/30/2026 | 1127791864 |
| Principal investigator 1 | Novavax Inc | $2,445.00 | 04/04/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055260259 |
| Principal investigator 1 | ModernaTX, Inc. | $600.00 | 03/29/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041718995 |
| Principal investigator 1 | ModernaTX, Inc. | $3,000.00 | 03/29/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041719793 |
| Principal investigator 1 | ModernaTX, Inc. | $25,204.40 | 03/29/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041720379 |
| Principal investigator 1 | Novavax Inc | $1,110.00 | 03/29/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055263253 |
| Principal investigator 1 | Novavax Inc | $2,029.00 | 03/24/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055264187 |
| Principal investigator 1 | Novavax Inc | $1,480.00 | 03/21/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055261257 |
| Principal investigator 1 | Novavax Inc | $1,295.00 | 03/15/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055265229 |
| Principal investigator 1 | Organon LLC | $1,892.70 | 03/15/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016107457 |
| Principal investigator 1 | Novavax Inc | $2,769.00 | 03/08/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055261259 |
| Principal investigator 1 | ModernaTX, Inc. | $1,200.00 | 03/03/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, | No dispute reported | 06/30/2026 | 1041720397 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,399.40 | 03/01/2023 | Non-covered Recipient Entity NEW ORLEANS CENTER FOR CLINICAL RESEARCH | PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT | No dispute reported | 06/30/2026 | 1006190767 |
| Principal investigator 1 | Novavax Inc | $370.00 | 02/28/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055260251 |
| Principal investigator 1 | PFIZER INC. | $3,030.21 | 02/24/2023 | Non-covered Recipient Entity Alliance for MultiSpeciality Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045907801 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 02/22/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, | No dispute reported | 06/30/2026 | 1041719007 |
| Principal investigator 1 | ModernaTX, Inc. | $26,931.45 | 02/22/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041720365 |
| Principal investigator 1 | Novavax Inc | $2,220.00 | 02/22/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055260255 |
| Principal investigator 1 | Organon LLC | $4,948.20 | 02/17/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016107657 |
| Principal investigator 1 | Novavax Inc | $2,399.00 | 02/16/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055260253 |
| Principal investigator 1 | Organon LLC | $3,000.00 | 02/10/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016082263 |
| Principal investigator 1 | Novavax Inc | $1,665.00 | 02/09/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055262287 |
| Principal investigator 1 | PFIZER INC. | $754.07 | 02/09/2023 | Non-covered Recipient Entity Alliance for MultiSpeciality Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY | No dispute reported | 06/30/2026 | 1045903111 |
| Principal investigator 1 | ModernaTX, Inc. | $24,363.30 | 02/03/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041719779 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 02/03/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041719787 |
| Principal investigator 1 | ModernaTX, Inc. | $8,360.00 | 02/03/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC - Newton - PPDS | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041839531 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,415.00 | 02/03/2023 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | Safety, Immunogenicity, Infectivity, and Dose-Finding Study of an Investigational Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers | No dispute reported | 06/30/2026 | 1035908481 |
| Principal investigator 1 | Novavax Inc | $4,735.00 | 02/02/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055266211 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $979.20 | 01/27/2023 | Non-covered Recipient Entity NEW ORLEANS CENTER FOR CLINICAL RESEARCH | PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT | No dispute reported | 06/30/2026 | 1006190757 |
| Principal investigator 1 | ModernaTX, Inc. | $25,981.15 | 01/25/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1041719773 |
| Principal investigator 1 | Novavax Inc | $2,372.00 | 01/25/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055265227 |
| Principal investigator 1 | Organon LLC | $1,485.90 | 01/25/2023 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC | OG-8175A-023 | No dispute reported | 06/30/2026 | 1016107443 |
| Principal investigator 1 | Novavax Inc | $2,733.00 | 01/20/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055266213 |
| Principal investigator 1 | Novavax Inc | $11,332.00 | 01/06/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 | No dispute reported | 06/30/2026 | 1055264185 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,433.90 | 01/04/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T | No dispute reported | 06/30/2026 | 1006190735 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,697.63 | 01/04/2023 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T | No dispute reported | 06/30/2026 | 1006190747 |